Clinical Trial Update: The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency [Phase 2]

View source ↗

Summary

The Phase 2 ENABLE study evaluating INZ-701 for ENPP1 deficiency and related diseases has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Hypophosphatemic Rickets
• Ectonucleotide Pyrophosphatase Phosphodiesterase Deficiency
• Generalized Arterial Calcification of Infancy

Drugs mentioned

• INZ-701

Snippet

Sponsor: Inozyme Pharma | Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 2 | Status: WITHDRAWN